Market research
ATXI Avenue Therapeutics Inc
PINK USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 849K
- P/E ratio
- Not available
- Analyst target
- 8
- Beta
- Not available
Profile
Company facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US05360L3042
- Market cap
- 849K
- P/E ratio
- Not available
- Analyst target
- 8
- Beta
- Not available
About
About Avenue Therapeutics Inc
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ATXI discussion.
5 years, 4 months ago
Avenue Therapeutics, Inc is currently in a long term downtrend where the price is trading 51.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Avenue Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 100.0% to $-5 since the same quarter in the previous year.
Finally, its free cash flow grew by 148.3% to $2M since the same quarter in the previous year.
Based on the above factors, Avenue Therapeutics, Inc gets an overall score of 3/5.